IFNA1 and cancer: As immune responses with strong Th1 bias are considered adequate for the induction of optimal antitumor immunity, IFN-DC represent highly promising candidates for the development of DC-based immunotherapy trials in cancer (major preclinical and clinical studies testing IFN-DC in cancer immunotherapy are summarized in Table 1).